Lidia Sambucetti
0000-0001-9686-5444
Publication & Citation Trends
Most Cited Works
Publications
87 total
Mega-High-Throughput Screening Platform for the Discovery of Biologically Relevant Sequence-Defined Non-Natural Polymers OA
Cited by 5
Semantic Scholar
Abstract 3335: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetration and antitumor activity in subcutaneous and intracranial NSCLC models
Cited by 4
Semantic Scholar
Abstract LB108: Validation of computationally predicted synthetic lethal interactions for KRAS
Cited by 0
Semantic Scholar
Structural insights into the function of the catalytically active human Taspase1. OA
Cited by 5
Semantic Scholar
New Structural Insights into the Function of the Active Full Length Human Taspase1: A Novel Anticancer Therapeutic Target OA
Cited by 1
Semantic Scholar
Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function OA
Cited by 11
Semantic Scholar
An exon skipping screen identifies antitumor drugs that are potent modulators of pre-mRNA splicing, suggesting new therapeutic applications OA
Cited by 12
Semantic Scholar
Abstract 4015: Synthetic lethality-based predictive biomarker identification of splicing modulators in lung cancer
Cited by 0
Semantic Scholar
Research Topics
RNA modifications and cancer
(12)
Cancer Research and Treatments
(10)
Computational Drug Discovery Methods
(9)
RNA Research and Splicing
(8)
RNA and protein synthesis mechanisms
(7)
Frequent Co-Authors
Affiliations
Novartis (Switzerland)
SRI International
Albert Einstein College of Medicine
University of California, Santa Cruz
University of Münster